|Articles|December 10, 2001

CDER News 12/5 and 12/6 2001

Author(s)BioPharm International Editors

New and generic drug approvals

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

WHO Finalizes United States’ Withdrawal from Organization: Report

ByNicholas Jacobus

January 22nd 2026

idea, light bulb, rocket, innovation, technology, business, development, imagination, inspiration, intelligence, hand hold light bulb to light up solution and advertise hit the goal and target rocket. | Image credit: © Garun Studios - stock.adobe.com

New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy

ByFeliza Mirasol

January 22nd 2026

Male Engineers Maintenance Robot Arm at Lab. he are in a High Tech Research Laboratory with Modern Equipment. Technology and Innovation Concept.Professional. | Image credit: © anon - © anon - stock.adobe.com

High-Throughput Systems Refine Protein Engineering

ByFeliza Mirasol

January 22nd 2026

Single helix RNA, Epigenetics concept | Image credit: © Artur - © Artur - stock.adobe.com

European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE

ByFeliza Mirasol

January 21st 2026

Bispecific antibody colored heavy chain in green and pink, light chain blue and yellow against gray background; glycosylated bispecific immunoglobulin engineered to target different antigens 3d render | Image credit: © huenstructurebio.com - © huenstructurebio.com - stock.adobe.com

Next-Generation Modalities Drive New Antibody Discovery

ByFeliza Mirasol

January 21st 2026

CDER News 12/5 and 12/6 2001

Newsletter

Related Content

WHO Finalizes United States’ Withdrawal from Organization: Report

New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy

High-Throughput Systems Refine Protein Engineering

European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE

Next-Generation Modalities Drive New Antibody Discovery

Trending on BioPharm International

Next-Generation Modalities Drive New Antibody Discovery

New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy

European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE

GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies

State of the Bio/Pharma Workforce: A Comparative Analysis of Employment Trends and Industry Sentiment